AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04802759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: 400 mg orally once a day on Days 1-21 of each 28-day cycle until unacceptable toxicity or disease progression
Study NCT04802759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inavolisib
Description: 9 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression
Study NCT04802759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: 600 mg orally once a day on Days 1-21 of each 28-day cycle until unacceptable toxicity or disease progression
Study NCT04802759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 10 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression
Study NCT04802759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Samuraciclib
Description: 360 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression
Study NCT04802759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PH FDC SC
Description: On Day 1 of Cycle 1 (1 cycle is 21 days), pertuzumab and trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) will be administered SC as a fixed dose formulation of 1200 mg pertuzumab, 600 mg trastuzumab, and 30,000 units hyaluronidase. On Day 1 of Cycles 2 and beyond, PH FDC SC will be administered SC once every 21 days as a fixed dose of 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase.
Study NCT06250452 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Halotherapy (Salt Therapy)
Description: Personal Information Form, SPO2 measurement and Asthma Symptom and Treatment Need Scoring / Daily Follow-up Form will be applied to the children in the experimental group before they are taken to the salt therapy room. Scales and SPO2 measurement will be performed before, during and after therapy. The same procedure will be applied to the children in the control group, but no therapy will be applied. In the study planned to be carried out for 6 weeks, it is recommended that children repeat the session for 10 minutes daily, the first 5 sessions every day and the other 5 weeks once a week.
Study NCT05631730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flecainide
Description: Flecainide is mainly used for pharmacological conversion in patients with atrial tachyarrhythmias and to suppress ventricular arrhythmias in patients with structurally normal hearts.
Study NCT05631730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: Metoprolol is a beta-blocker and class II antiarrhythmic drug considered standard care in most cardiac diseases predisposing to ventricular arrhythmias, including arrhythmic mitral valve prolapse.
Study NCT05631730 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: Metoprolol is a beta-blocker and class II antiarrhythmic drug considered standard care in most cardiac diseases predisposing to ventricular arrhythmias, including arrhythmic mitral valve prolapse.
Study NCT04802759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH FDC SC
Description: On Day 1 of Cycle 1 (1 cycle is 21 days), pertuzumab and trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) will be administered SC as a fixed dose formulation of 1200 mg pertuzumab, 600 mg trastuzumab, and 30,000 units hyaluronidase. On Day 1 of Cycles 2 and beyond, PH FDC SC will be administered SC once every 21 days as a fixed dose of 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase.
Study NCT04802759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: 125 mg orally once a day on Days 1-21 during each 28-day cycle until unacceptable toxicity or disease progression
Study NCT06014476 — intervention group
Intervention type: OTHER
Intervention: questionnaires
Description: Sent questionnaires to caregivers and used CRS-R to assess patients with DoC
Study NCT05707520 — intervention group
Intervention type: DRUG
Intervention: enteric-coated mycophenolate (MPAs)
Description: Immunosuppression protocol with enteric-coated mycophenolate sodium
Study NCT05707520 — intervention group
Intervention type: DRUG
Intervention: None MPA
Description: Immunosuppression protocol without enteric-coated mycophenolate sodium
Study NCT04802759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 840 mg by intravenous (IV) infusion on Days 1 and 15 each 28-day cycle.
Study NCT06331182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Patients will receive external oblique intercostal plane block using 29 ml bupivacaine 0.25% + 1 ml ketamine (50 mg) after induction of general anesthesia.
Study NCT06331182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patients will receive external oblique intercostal plane block using 29 ml bupivacaine 0.25% + 1 ml dexmedetomidine 0.5 μg/kg after induction of general anesthesia.
Study NCT06331182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 29 ml bupivacaine 0.25%
Study NCT05611034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin infusion in single lung via IVLP technique
Study NCT06065319 — intervention group
Intervention type: DEVICE
Intervention: Wearable Sensors
Description: Participants will wear smartwatches and smartrings and this data will be used to design algorithms which seek to find associations between device data and recovery.
Study NCT05480189 — intervention group
Intervention type: OTHER
Intervention: Non-intervention
Description: Non-intervention,with real world study
Study NCT06289920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR3005
Description: One tablet administered alone, Once a day
Study NCT06289920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BR3005-1
Description: One tablet administered alone, Once a day
Study NCT06289920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BR3005-2
Description: One tablet administered alone, Once a day
Study NCT06200233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivoceranib
Description: 700mg once daily
Study NCT02969512 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIPPER
Description: Participants can complete the online educational modules at home or another location with internet access. The total time to complete all of the modules is about 2 hours and 30 minutes.
Study NCT02969512 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OASIS Online Educational Webinars
Description: 2-hour online educational large group sessions
Study NCT06538337 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam Radiotherapy
Description: Five fractions of radiation therapy using adaptive planning and CT or MRI guidance (6 Gy per fraction) delivered once every other day excluding weekends and holidays
Study NCT05643521 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary composition of macronutrients and calories
Description: Carbohydrate restriction
Study NCT05465668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP16001 Drug A
Description: DWP16001 Drug A
Study NCT05465668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP16001 Drug C
Description: DWP16001 Drug C
Study NCT05576415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline Tartrate Nasal Spray
Description: Intranasal delivery of OC-01 (varenicline solution) 0.6 mg/mL twice a day (BID) for 28 days.
Study NCT06352502 — intervention group
Intervention type: DRUG
Intervention: Furmonertinib
Description: Patients treated with Furmonertinib mesilate tablets orally
Study NCT05781334 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Consult Intervention
Description: The intervention will consist of a quality improvement (QI)-based virtual consult designed by a multi-disciplinary team that will aim to address provider-level, patient-level, and system-level barriers to cardio-renal-metabolic disease medications
Study NCT05297552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48-ADC
Description: Drug: RC48-ADC 2.0 mg/kg by intravenous (IV) infusion, given on Day 1 of each 14-day cycle
Study NCT05297552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS001
Description: Drug: JS001 3.0 mg/kg by intravenous (IV) infusion, given on Day 1 of each 14-day cycle
Study NCT05594667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: 25mg of psilocybin provided by Filament Health
Study NCT05281549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase
Description: Alteplase 0.9mg/kg are being used.
Study NCT05281549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Description: Tenecteplase 0.25mg/kg are being used.
Study NCT05281549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Description: Tenecteplase 0.4mg/kg are being used.
Study NCT05981755 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing tasks
Description: Breathing tasks include normal breathing through nose or mouth, breathing while resting wakefully, increase and decrease in breathing rate, and breath counting.
Study NCT05981755 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain mapping with stimulation
Description: Electrical stimulation will be used to find specific areas of the brain involved in breathing function. Stimulation will be applied using a Nihon Kohden MEE-1000A neural function measuring system with the MS-120BK extension unit for brain stimulation.
Study NCT04921969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: The study cream will be applied topically twice a day for up to 52 weeks.
Study NCT04921969 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: Matching vehicle cream will be applied topically twice a day for up to 8 weeks.
Study NCT05190757 — intervention group
Intervention type: OTHER
Intervention: Airway and Ventilation
Description: Insertion of Laryngeal Mask airway for ventilation or use of Face Mask
Study NCT06281665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Description: The intervention group will receive low-dose \[81 mg\] aspirin pill daily for 6 months.
Study NCT06281665 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The control group will receive similar appearing placebo daily for 6 months.
Study NCT04101851 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: omission of SLNB
Description: After radiologic complete remission at the end of NAST all patients will be treated with breast-conserving surgery alone without any axillary surgery.
Study NCT06414148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Epcoritamab will be administered as a 28-day cycle. In Cycle 1 and 2, epcoritamab will be given with step up dosing in Cycle 1. From Cycle 3 onwards dosing will be on Day 1 and 15 of each cycle.
Study NCT06414148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab, lenalidomide and rituximab
Description: Treatment with epcoritamab will be administered following the same dosing schedule as Arm A. On days where rituximab and/or lenalidomide are also due, epcoritamab should be administered last.~Patients will receive lenalidomide once daily on Day 1-21 of each 28-day cycle, starting at Cycle 1 through to Cycle 6.~Patients will receive rituximab administered by intravenous (IV) infusion on Day 1, 8, 15 and 22 of Cycle 1 and on Day 1 only of Cycles 2-6.
Study NCT05970133 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colectomy with NOSE procedure
Description: The specimen will be extract from the anus.
Study NCT05970133 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colectomy with NOSE procedure
Description: The specimen will be extract from the anus.
Study NCT06228066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: Lurbinectedin is administered IV over 1 hour at 3.2 mg/m2 on day 1 of each 21-day cycle
Study NCT06228066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab is administered IV at 800 mg over 1 hour on day 1 of each 21-day cycle
Study NCT06474507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calculus bovis sativus (CBS)
Description: Subjects will orally receive 100mg CBS per day from day 1 to day 84.
Study NCT05892003 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phase 1 Control
Description: Control diet (30% Fat, 15% Protein, 55% Carbohydrate, Fibre rising from 10 to 16g/d). Fed to energy balance (1.5 x Resting Metabolic Rate, RMR).
Study NCT05892003 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phase 2 High Fibre Weight Loss
Description: High Fibre Weight Loss diet (30% Fat, 15% Protein, 55% Carbohydrate). Fed to energy deficit (100% RMR). The quantity of fructo-oligosaccharides (FOS) will be fixed at 20g/day for all kcal levels with additional fibre coming from the diet provided. The FOS will be split over breakfast, lunch and dinner in drinks/yoghurts which will be compulsory to consume.
Study NCT05714852 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy eating
Description: Promotion of healthy eating
Study NCT05518214 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot
Description: Participants receive a 12-week supply of beetroot juice.
Study NCT05518214 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants receive a 12-week supply of placebo beetroot juice.
Study NCT04989140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Ixazomib Drug:pomalidomide Drug:dexamethasone
Description: Treatment was continued until disease progression, unacceptable toxicity
Study NCT05892003 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phase 3 High Fibre and Non-Nutritive Sweetener Weight Loss
Description: High Fibre and Non-Nutritive Sweetener Weight Loss diet (30% Fat, 15% Protein, 55% Carbohydrate). Fed to energy deficit (100% RMR). The quantity of fructo-oligosaccharides (FOS) and non-nutritive sweetener (sucralose) will be fixed at 20g/day and 30mg/day respectively for all kcal levels with additional fibre coming from the diet provided. The FOS and sucralose will be split over breakfast, lunch and dinner in drinks/yoghurts which will be compulsory to consume.
Study NCT04686084 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual-energy computed tomography scan
Description: Diagnostic CT scan
Study NCT05116111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHA1402 tablets
Description: SYHA1402 tablets, oral, twice daily
Study NCT05116111 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, oral, twice daily
Study NCT05116111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, oral, twice daily
Study NCT05260450 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1064 nm Nd:YAG-laser therapy
Description: All interventions and mycological tests for each subject were performed over the course of one day.~After subjects were included, toenails with a clinical suspicion of OM were tested for fungal infection by culture and microscopy. At the same time, nail clippings from said toenails were obtained and randomised into one of two treatment groups, i.e., group A and group B.~The nail clippings were then treated with a 1064 nm Nd:YAG-laser with laser settings as specified by the treatment groups. All nail clippings were treated only once.~Immediately after treatment, nail clippings were again tested for fungal infection by culture and microscopy.
Study NCT05260450 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1064 nm Nd:YAG-laser therapy
Description: All interventions and mycological tests for each subject were performed over the course of one day.~After subjects were included, toenails with a clinical suspicion of OM were tested for fungal infection by culture and microscopy. At the same time, nail clippings from said toenails were obtained and randomised into one of two treatment groups, i.e., group A and group B.~The nail clippings were then treated with a 1064 nm Nd:YAG-laser with laser settings as specified by the treatment groups. All nail clippings were treated only once.~Immediately after treatment, nail clippings were again tested for fungal infection by culture and microscopy.
Study NCT05256199 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidomain lifestyle intervention
Description: A multidomain lifestyle intervention, including (1) physical activity, (2) cognitive training, (3) cardiovascular risk factor management (Cardiovascular), (4) dietary counselling, (5) Souvenaid, (6) sleep counselling, (7) stress management, and (8) social activities.
Study NCT06110858 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tinkering Activities
Description: Tinkering activities encompass elements of science, art and technology. They emphasize that learning is not simply about teachers imparting knowledge to students, but rather about students actively constructing knowledge themselves. Tinkering activities are characterized by three key elements: active engagement, open-ended exploration and problem-solving. In such activities, participants are provided with products without telling the steps. They are then encouraged to attempt creating it on their own. During this hands-on learning process, participants need to flexibly change their mindset, think outside the box and tackle emerging problems, which challenge their executive functions.
Study NCT06047548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC
Study NCT05004909 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.05% Tretinoin
Description: Topical 0.05% tretinoin cream applied daily every night by the subjects according to assigned randomization
Study NCT04411225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol oral solution
Description: Both the active drug (cannabidiol) and placebo will be in oral solution.
Study NCT04411225 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cannabidiol oral solution
Description: Both the active drug (cannabidiol) and placebo will be in oral solution.
Study NCT05692206 — intervention group
Intervention type: OTHER
Intervention: evaluation
Description: Surveys will be administered to the participants. Participants will be given a stroop TBAG test.
Study NCT06376812 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Description: Physical activity
Study NCT06047548 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT05678179 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth
Description: Patients will participate in standard clinical practice for bariatric surgery preparation with 50% of visits occurring via telehealth.
Study NCT05678179 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In Person (Face-2-Face)
Description: Patients will participate in standard clinical practice for bariatric surgery preparation with face-2-face clinic visits.
Study NCT06031844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFV890
Description: oral film-coated tablets
Study NCT06031844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral film-coated tablets
Study NCT06031844 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral film-coated tablets
Study NCT06529978 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoreMap EP Mapping System Mapping
Description: Endocardial mapping to collect and analyze high fidelity endocardial EGMs in patients with persistent and long-standing persistent AF.
Study NCT06529978 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoreMap EP Mapping System Map-Guided Ablation
Description: Initial development and evaluation of a map-guided tailored ablation strategy and to demonstrate safety and chronic efficacy of the CoreMap EP Mapping System.
Study NCT06282952 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fecal transplant
Description: At delivery, the fecal transplant is thawed and 0.5 mL representing 3.5 mg of the mother's or donors' fecal sample is dissolved in 5 mL of the mother's own milk or when not available pasteurized bank milk. The sample is given orally to newborn infants as soon as possible but not later than 6 h of delivery and not later than two hours after defrosting.
Study NCT06282952 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fecal transplant
Description: At delivery, the fecal transplant is thawed and 0.5 mL representing 3.5 mg of the mother's or donors' fecal sample is dissolved in 5 mL of the mother's own milk or when not available pasteurized bank milk. The sample is given orally to newborn infants as soon as possible but not later than 6 h of delivery and not later than two hours after defrosting.
Study NCT05972122 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Analgesia management; group S and C
Description: Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient-controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol including 10 mcg bolus without infusion dose, 10 min lockout time, and 4-hour limit. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.